Tyra Biosciences is a clinical-stage biotechnology company developing next-generation precision medicines for targeted oncology and genetically defined conditions, focusing on Fibroblast Growth Factor Receptor (FGFR) biology. The company utilizes its proprietary SNÅP platform to design oral small molecule product candidates that address difficult-to-drug targets. Its lead program, oral dabogratinib, is being advanced in Phase 2 trials for low-grade upper tract urothelial carcinoma, intermediate risk non-muscle invasive bladder cancer, and achondroplasia. Other pipeline assets include TYRA-430, an FGFR4/3 biased inhibitor for hepatocellular carcinoma, and TYRA-200, an FGFR1/2/3 inhibitor designed to overcome resistance mutations in intrahepatic cholangiocarcinoma. Tyra Biosciences retains full development and commercialization rights for its in-house developed pipeline, with a strategy to advance candidates toward pivotal studies and commercialization in the United States and other territories.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage tyra.bio
Sector Healthcare IR page ir.tyra.bio
Tags
oncology, rare disease, fgfr inhibitors, small molecules, urothelial cancer, skeletal dysplasia, precision medicine, drug discovery, SNÅP, dabogratinib, TYRA-300, TYRA-430, TYRA-200, SURF301, SURF303, SURF302, BEACH301, SURF431, SURF201
Press page —

Metrics

Valuation  
Market cap $ 1.509B
Market cap (USD) $ 1.509B
P/E -8.28
PEG —
P/BV 2.18
P/S —
P/OCF -12.63
P/FCF -12.59
Dividend yield —
Turnover / mcap —
Returns  
ROE -39.8%
ROI -64.1%
ROIC -53.2%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 2
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 282.609M 363.558M 225.857M 266.181M 306.701M —
Net profit -119.947M -86.481M -69.134M -55.325M -26.294M 0
Free cash flow -95.283M -70.438M -50.909M -50.844M -24.406M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 26.29 13.9 13.85 7.6 14.07 —
Price performance 12m 0.89 0 0.82 -0.46 — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 133,000 1.18M 2.62M 6.5M 6.22M 5.81M
Cash and deposits (USD) 108,000 15.2M 302M 251M 58M 92M 77.4M
Right-of-use assets (USD) — 148,000 — — — — 5.57M
Cash flow detail
Operating cash flow (USD) — -7.76M -23.7M -50.3M -50.1M -69.8M -95.1M
Purchases of property, plant and equipment (USD) — -312,000 -661,000 -559,000 -770,000 -664,000 -141,000
Change in payables (cash effect) (USD) — 1.02M 1.49M 2.36M 9.37M -744,000 3.37M
Interest paid (cash effect) (USD) — -1,000 0.00 — — — —
Share-based compensation (USD) — 439,000 2.89M 10.6M 13.5M 22.8M 28M
Free cash flow (OCF - PPE - intangibles) (USD) — -8.08M -24.4M -50.8M -50.9M -70.4M -95.3M
Income detail
Research and development expense (USD) — 7.2M 20.6M 43M 62.5M 80.1M 103M
↳ 5y CAGR +70.2%
Total comprehensive income (USD) — — — -55.3M -68.8M -86.1M -120M
Comprehensive income to owners (USD) — — — -55.3M -68.8M -86.1M -120M
Reported Nov 3, 2021 Mar 3, 2022 Mar 3, 2022 Mar 19, 2024 Mar 19, 2024 Mar 27, 2025 Aug 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients

Completed $400 million financing, providing additional capital to advance dabogratinib’s 3x3 strategy

Cash runway through 2030 with cash, cash equivalents and marketable securities of $700.5 million as of September 30, 2026

CARLSBAD, Calif., November 10, 2026 – Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate progress.

“2026 has been a defining year for TYRA. With the initial results from SURF302 in the ablative setting, we believe dabogratinib has the potential to be the first oral FGFR3-selective inhibitor in intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), reinforcing our conviction in the potential of precision FGFR3 inhibition to fundamentally change the treatment paradigm for patients,” said Todd Harris, PhD, President and Chief Executive Officer of TYRA.

Figure 2. Study Design of BEACH301 Cohorts 1 and 2* N=* ACH age 5-10 No run-in Anticipate n=~25 total enrollment DOSE (mg/kg) Natural Hx (6 mo) 0612 months on treatment 6 6 6 6 0.50 60.625 0.375 0.25 0.125 DOSE (mg/kg) 0.50 0.625 0.375 0.25 0.125 *Cohort 1 (6-mo run-in) Sentinel Safety Cohort *Cohort 2 (6-mo run-in) Treatment naïve; ACH age 3-10 Received prior growth-accelerating therapy; ACH age 3-10 ✓ Indicates that the dose level has been cleared by an independent Data Safety Monitoring Committee.*Dose decisions based on 6 participants. Additional participants may be assigned at discretion of Sponsor. Schematic representation of the study design, illustrating cohort structure and weight-based dabogratinib dosing. Participant Criteria 13 Key Inclusion CriteriaKey Exclusion Criteria • Children aged 3 to 10 years of age • Molecularly confirmed achondroplasia with FGFR3 G380R mutation • Radiographically confirmed open growth plates by bone age X-ray • Ability to stand and ambulate independently • Sentinel Safety Cohort only: aged 5 to 10 years old (inclusive) • Cohort 1 only: aged 3 to 10 years old (inclusive) and are naïve to prior growth-accelerating therapy • Cohort 2 only: aged 3 to 10 years old (inclusive) and have received prior growth-accelerating therapy • Ability to take oral medication • Presence or history of any concurrent disease or condition that would interfere with study participation, safety evaluations, or any uncontrolled or untreated condition that could impact pediatric growth • Endocrine condition that alters calcium/phosphate homeostasis • Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study • History or current evidence of corneal or retinal disorder/keratopathy • Presence of guided growth hardware (eg, 8 plates). Planned or anticipated orthopedic surgeries Study Endpoints 13 Primary EndpointsSecondary Endpoints • Incidence of treatment-emergent AEs • Change from baseline in AGV • Change from baseline in height z-score • Comparison of single- and multiple-dose sparse pharmacokinetic parameters, including but not limited to C max , T max , AUC 0-last , AUC Ta u , AUC 0-∞ , Vd/F, CL/F, and t ½ • Change from baseline in anthropometric measurements, including but not limited to standing height, sitting height, upper arm length, lower arm length, tibial length, femur length, arm span proportionality (arm span/height ratio), and upper segment/ lower segment ratio with dabogratinib BACKGROUND • Achondroplasia is the most common form of heritable skeletal dysplasia, affecting approximately 250,000 people worldwide 1,2

• Achondroplasia is caused by a gain of function mutation in the FGFR3 gene (most commonly G380R) leading to overactivation of FGFR3 signaling 1-4 • Aberrant FGFR3 signaling inhibits chondrocyte proliferation and differentiation, resulting in impaired endochondral ossification and abnormal skeletal development (Figure 1) 2,3,5 • Individuals with achondroplasia can experience lifelong morbidity, with early- life complications including foramen magnum stenosis, recurrent otitis media, sleep-disordered breathing, and ongoing impact across childhood and adulthood including obesity, skeletal complications, chronic pain, surgeries, and effects on function and psychosocial well-being 1,3,6,7 • Inhibiting FGFR3 may benefit children with achondroplasia. Approved CNP analogs indirectly modulate this pathway, 2,8,9 while pan-FGFR inhibition
has demonstrated encouraging safety and efficacy, supporting direct
FGFR inhibition 10 −Dabogratinib is an oral, highly selective FGFR3 inhibitor designed to directly target the underlying driver of achondroplasia while minimizing off-target effects 11 −By avoiding the toxicities associated with inhibition of FGFR1, FGFR2, and FGFR4, dabogratinib may provide greater efficacy with a larger therapeutic window than non-isoform selective FGFR inhibitors 12 −Dabogratinib is being evaluated in children with achondroplasia in the phase 2 BEACH301 study (NCT06842355) 13 METHODS • BEACH301 (NCT06842355) is a phase 2, multicenter, open-label, dose- escalation/dose-expansion study to evaluate the safety, tolerability, and potentially effective dose(s) of oral dabogratinib QD in children aged 3 to

10 years with achondroplasia with open growth plates 13

• Dabogratinib is administered at weight-based dose levels (0.125-0.625 mg/kg),

with dose escalation per protocol-defined criteria • The study includes 3 cohorts (Figure 2) −Sentinel Safety Cohort −Cohort 1: Treatment-naïve −Cohort 2: Received prior growth-accelerating therapy Abbreviations ACH, achondroplasia; AE, adverse event; AGV, annualized growth velocity; AUC 0-last , area under the curve from time zero to the last measurable concentration; AUC tau , area under the curve from time zero to tau; AUC 0-∞ , area under the curve from time zero to infinity; CL/F, apparent clearance; C max , maximum plasma concentration; CNP, C-type natriuretic peptide; FGFR, fibroblast growth factor receptor; Hx, history;

mo, month; QD, once daily; t ½ , half-life; T max , time to maximum concentration; Vd/F, apparent volume
of distribution. References

  1. Pauli RM. Orphanet J Rare Dis. 2019;14(1):1. 2. Ornitz DM and Legeai-Mallet L. Dev Dyn. 2017;246(4): 291-309. 3. Chamarthi VS, et al. Achondroplasia. Treasure Island (FL): StatPearls Publishing; 2026.
  2. Monsonego-Ornan E, et al. Mol Cell Biol. 2000;20(2):516-522. 5. Tyra Biosciences, Inc. Corporate presentation. December 2025. 6. Hoover-Fong J, et al. Pediatrics. 2020;145(6):e20201010. 7. Hecht JT,

et al. Am J Med Genet. 1989;32(4):528-535. 8. Savarirayan R, et al. Lancet. 2020;396(10252):684-692.
9. Savarirayan R, et al. JAMA Pediatr. 2026;180(1):18-25. 10. Savarirayan R, et al. N Engl J Med. 2025;392(9): 865-874. 11. Starrett JH, et al. Mol Cancer Ther. 2026;25(3):408-415. 12. Hudkins RL, et al. J Med Chem. 2024;67(18):16737-16756. 13. National Library of Medicine. NCT06842355. Accessed September 25, 2026. https://clinicaltrials.gov/study/NCT06842355. Acknowledgments The authors would like to thank the patients, caregivers, and the BEACH301 investigators and study personnel at study sites. Medical writing assistance was provided by Federica Rinaldi, PhD, of MEDiSTRAVA (Yardley).

This study is funded by Tyra Biosciences. Sponsor Contact Information [email protected] l Tyra Biosciences, Inc. l Carlsbad, CA, USA Presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting; October 9–12, 2026; Boston, MA, USA Content of this poster is copyrighted by Tyra Biosciences, Inc. Permission is required for reuse. Figure 1. Aberrant FGFR3 Signaling in Achondroplasia GERMLINE AL TERATIONS Downstream: CNP inhibits some path ways activated by FGFR3 G380R Over-activated FGFR3 signaling slows chondrocyte proliferation (‘brake’) FGFR3FGFR3 FGF P P P P Gain-of-function FGFR3 mutations (eg, G380R) lead to overactivation of FGFR3 signaling (via an increase in steady-state levels of receptor), 4

inhibiting chondrocyte proliferation and impairing endochondral

bone growth. A Multicenter, Phase 2, Dose-Escalation/Dose-Expansion Study of Dabogratinib (Formerly TYRA-300)
in Children With Achondroplasia With Open Growth Plates: BEACH301 Klane White, 1 Ricki S. Carroll, 2 Michael Stalvey, 3 Carl Decker, 3 Andrew Barrett, 3 Will Charlton, 4 Ravi Savarirayan 5 1 Children’s Hospital Colorado, Denver, CO; 2 Nemours Children’s Hospital, Wilmington, DE; 3 Tyra Biosciences, Inc., Carlsbad, CA; ⁴Work completed while the author was an employee of Tyra Biosciences, Inc., Carlsbad, CA, USA;
5 Murdoch Children’s Research Institute, Royal Children’s Hospital, Melbourne, VIC, Australia. SITE LIST UNITED STATES • Torrance, CA • Aurora, CO • Wilmington, DE • Baltimore, MD • Chevy Chase, MD • Columbia, MO • St. Louis, MO
• Durham, NC • Nashville, TN • Dallas, TX • Madison, WI Site list reflects participating centers as of September 25, 2026. CANADA • Toronto • Edmonton • Ottawa • Montreal AUSTRALIA • Parkville EUROPE • Paris, France • Utrecht, Netherlands • Vitoria, Spain • Madrid, Spain • Stockholm, Sweden UK • Sheffield • London −Great Ormond Street Hospital −Guy’s and St Thomas’ NHS Foundation Trust SAT-474

Prenatal treatment with dabogratinib increases both long bones and size of the foramen magnum and delays premature fusion of synchondroses in a mouse model mimicking achondroplasia Clara Lemoine 1 , Jacqueline H. Starrett 2 , Ronald V. Swanson 2 , Laurence Legeai-Mallet 1 Achondroplasia (ACH) is the most common form of heritable skeletal dysplasia, affecting approximately 250,000 people worldwide. 1,2 ACH is caused by a gain of function variant in the FGFR3 gene, most commonly G380R in >99% of cases. 1-4 Aberrant FGFR3 signaling inhibits chondrocyte proliferation and differentiation, resulting in impaired endochondral ossification and abnormal skeletal development. 2,3 Individuals with ACH can experience lifelong morbidity, with early complications including foramen magnum stenosis, recurrent otitis media, sleep-disordered breathing, INTRODUCTION Achondroplasia RESULTS Prenatal plus postnatal treatment with dabogratinib increased the size of the foramen magnum Dabogratinib is an oral, highly selective FGFR3 inhibitor designed to directly target the underlying driver of ACH while minimizing off- target effects. 13 By avoiding toxicities associated with inhibition of FGFR1, FGFR2, and FGFR4, dabogratinib may provide greater efficacy with a larger therapeutic window than non- isoform selective FGFR inhibitors. 14 Dabogratinib was previously evaluated in the Fgfr3 Y367C/+ mouse model mimicking the phenotype of ACH 15 , in which postnatal treatment from birth resulted in significant increases in long bone lengths and cranial growth. 16 Dabogratinib is currently being evaluated in a Phase 2 trial in children ages 3-10 with ACH, BEACH301 (NCT06842355). Dabogratinib

  1. Université de Paris Cité,

Imagine Institute, Genetics of development disorders INSERM UMR1163, Paris, France; 2. TYRA Biosciences, Carlsbad, California, USA. E-mail address: [email protected] In the current study, pregnant mice were treated with 2.7 mg/kg SC dabogratinib from embryonic day 14.5 (E14.5) through birth, then neonatal Fgfr3 Y367C/+ mice were treated with either vehicle or 1.2 mg/kg SC dabogratinib from 1 day after birth for 15 days (right). REFERENCES 1.Pauli et al., Orphanet J Rare Dis, 2019 2.Ornitz and Legeai-Mallet, Dev Dyn, 2017 3.Chamarthi, et al., StatPearls, 2025 4.Monsonego-Ornan et al., Mol Cell Biol, 2000 5.Hoover-Fong et al., Pediatrics, 2020 6.Hecht et al., Am J Med Genet, 1989 7.Hoover-Fong et al., Bone, 2021 8.Legare et al., J Neurosurg Pediatr, 2021 9.Vallin et al., J Gynecol Obstet Hum Reprod, 2025 10.Savarirayan et al., Lancet, 2020 11.Savarirayan et al., JAMA Pediatr, 2026 CLINICAL TRIAL POSTNATAL: (Previous study 16 ) PRENATAL + POSTNATAL: (New study) P16 Fgfr3 Y367C/+ Fgfr3 Y367C/+ mice treated with vehicle have premature fusion of the IOSA, while postnatal dabogratinib treatment resulted in partially open IOSA (left) and increased the area of the foramen magnum by 25.2% (below). 16 Prenatal plus postnatal treatment with dabogratinib further delayed the premature fusion of the synchondroses, resulting in open IOSA (left) and a 35.1% increase in the area of the foramen magnum (below). IOSA: int raoccipital synchondroses anterior ISS: intersphenoidal synchondrosis SOS: spheno-occipital synchondrosis On the final day of treatment, skulls were collected for μCT imaging of the foramen magnum (bottom left). The area of the foramen magnum was quantified from the μCT images (bottom right). Prenatal plus postnatal treatment delayed the premature fusion of synchondroses The level of fusion of the IOSA, SOS and ISS were graded using the μCT images. 0 denotes an open and 5 denotes a closed synchondrosis. and ongoing impact across childhood and adulthood. 1,3,5,6 Critical foramen magnum stenosis requires surgical decompression in 20% of infants with ACH and in severe cases can result in sudden death. 7,8 Prenatal MRIs have detected foramen magnum stenosis in utero in several case reports. 9 Approved CNP analogs indirectly modulate the FGFR3 pathway, 2,10,11

while pan-FGFR inhibition has demonstrated encouraging safety and efficacy, supporting direct FGFR inhibition. 12 There is an unmet medical need for non-surgical therapies to address foramen magnum stenosis in infants. Dabogratinib FGFR3 Sentinel Safety Cohort ACH age 5-10 No run-in Anticipate n=~25 total enrollment 0.625 0.50 0.375 0.25 DOSE (mg/kg) Cohort 1 (6-mo run-in) Treatment naïve; ACH age 3-10 0.625 0.50 0.375 0.25 6 6 6 6 DOSE (mg/kg)N=* Natural Hx (6 mo)0612 Cohort 2 (6-mo run-in) Received prior growth-accelerating therapy; ACH age 3-10 months on treatment Cohorts 1 and 2 ** Dose decisions based on 6 participants. Additional participants may be assigned at discretion of Sponsor. The authors would like to thank Rob Wishnowsky of Cruxio, Inc., for their contributions to the poster. Download a copy of this poster here IOSA IOSA 12.Savarirayan et al., N Engl J Med, 2026 13.Starrett et al., Mol Cancer Ther, 2026 14.Hudkins et al., J Med Chem, 2024 15.Pannier et al., Biochem Biophys Acta, 2009 16.Starrett et al., JCI Insight, 2025 Prenatal treatment increased long bone length On the final day of treatment, long bones and L4-L6 lumbar vertebrae were measured by caliper. All lengths increased significantly. Length (mm) Fgfr3 +/+ Fgfr3 Y367C/+ Tibia Length (mm) Fgfr3 +/+ Fgfr3 Y367C/+ Femur Length (mm) Fgfr3 +/+ Fgfr3 Y367C/+ Ulna Length (mm) Fgfr3 +/+ Fgfr3 Y367C/+ Humerus Length (mm) Fgfr3 +/+ Fgfr3 Y367C/+ L4-L6 IOSA Foramen Magnum IOSA SOS ISS Area (mm 2 ) Fgfr3 +/+ Fgfr3 Y367C/+ Foramen Magnum Mann-Whitney U test vs. vehicle *** p < 0.001 Mann-Whitney U test vs. vehicle *** p < 0.001 chondrocyte differentiation chondrocyte proliferation STAT FRS2 GRB2 Raf ERK 1/2 NUCLEUS PP FGFR3 G380R dabogratinib TYRA Biosciences funded this research. LB-P2079 Fgfr3 Y367C/+ dabogratinib: postnatal Fgfr3 Y367C/+ vehicle Fgfr3 Y367C/+ dabogratinib: prenatal + postnatal Fgfr3 +/+

vehicle P12P8P4E16 P1 P1 Birth E14.5 2.7 mg/kg 1.2 mg/kg 1.2 mg/kg ISS Grade Percent Fgfr3 +/+ Fgfr3 Y367C/+ IOSA Grade Fgfr3 +/+ Fgfr3 Y367C/+ SOS Grade Percent Fgfr3 +/+ Fgfr3 Y367C/+ G3 Percent G0 G0 G4 G5 G0 G3 G1 G1 G3 G4 G4 G4 G5 G5 G0 G4 G5 G5G5 G3 Complete (100%) Near-complete (75-100%) Advanced (50-75%) Partial (25-50%) Early-stage (0-25%) None (open synchondroses) (0%) Fusion Grades 5 4 3 2 1 0 Fgfr3 Y367C/+ mice have premature fusion of the IOSA which was delayed with dabogratinib treatment. Prenatal plus postnatal treatment had a greater effect than postnatal treatment alone. As with the IOSA, both the SOS and ISS were prematurely fused at P16 in Fgfr3 Y367C/+ mice. Postnatal treatment did not significantly affect premature fusion of the SOS and ISS, while prenatal plus postnatal treatment had a partial effect on delaying the premature fusion of the SOS and ISS. 0.1256 0.125 prenatal: + _ ++ prenatal: + _ ++ prenatal: + _ ++     Fgfr3 Y367C/+

Prompts

Tyra Biosciences, Inc. (ticker TYRA), listed in United States.

ETFs Holding Tyra Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
CANC 1.01% 85,323 $ 2.136M Aug 31, 2026
ESSC 0.22% 2,506 $ 79.891K Jul 31, 2026
TMSL 0.08% 68,709 $ 2.195M Jun 30, 2026
VFMO 0.07% 57,079 $ 1.429M Aug 31, 2026
FFSM 0.07% 33,485 $ 1.068M Jul 31, 2026
FSEV 0.07% 148 $ 4,727.12 Jun 30, 2026
RESM 0.05% 52 $ 1,660.88 Jun 30, 2026
FESM 0.04% 75,538 $ 2.413M Jun 30, 2026
DFAS 0.01% 132,496 $ 2.619M Nov 12, 2026
MSSM 0.00% 942 $ 23.578K Aug 31, 2026
DCOR 0.00% 39,503 $ 780.777K Nov 12, 2026
DFAC 0.00% 62,536 $ 1.236M Nov 12, 2026
DFUS 0.00% 11,840 $ 234.018K Nov 12, 2026
DFAU 0.00% 1,377 $ 27.216K Nov 12, 2026
AVSU 0.00% 10 $ 197.40 Nov 16, 2026